HIV Envelope Protein gp41
"HIV Envelope Protein gp41" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Transmembrane envelope protein of the HUMAN IMMUNODEFICIENCY VIRUS which is encoded by the HIV env gene. It has a molecular weight of 41,000 and is glycosylated. The N-terminal part of gp41 is thought to be involved in CELL FUSION with the CD4 ANTIGENS of T4 LYMPHOCYTES, leading to syncytial formation. Gp41 is one of the most common HIV antigens detected by IMMUNOBLOTTING.
| Descriptor ID |
D015700
|
| MeSH Number(s) |
D12.776.543.512.500.330 D12.776.964.775.325.164.200 D12.776.964.775.562.500.200 D12.776.964.970.880.325.164.200 D12.776.964.970.880.910.330 D23.050.327.520.330
|
| Concept/Terms |
HIV Envelope Protein gp41- HIV Envelope Protein gp41
- Envelope Protein gp41, HIV
- HTLV-III gp41
- gp41(HIV)
- HIV Transmembrane Protein gp41
- env Protein gp41, HIV
- gp41 Envelope Protein, HIV
|
Below are MeSH descriptors whose meaning is more general than "HIV Envelope Protein gp41".
Below are MeSH descriptors whose meaning is more specific than "HIV Envelope Protein gp41".
This graph shows the total number of publications written about "HIV Envelope Protein gp41" by people in this website by year, and whether "HIV Envelope Protein gp41" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2002 | 1 | 0 | 1 |
| 2004 | 2 | 1 | 3 |
| 2005 | 1 | 0 | 1 |
| 2006 | 1 | 1 | 2 |
| 2007 | 0 | 1 | 1 |
| 2008 | 1 | 0 | 1 |
| 2009 | 3 | 0 | 3 |
| 2011 | 2 | 1 | 3 |
| 2012 | 3 | 1 | 4 |
| 2013 | 3 | 0 | 3 |
| 2015 | 3 | 0 | 3 |
| 2016 | 1 | 3 | 4 |
| 2017 | 12 | 8 | 20 |
| 2018 | 8 | 5 | 13 |
| 2019 | 5 | 5 | 10 |
To return to the timeline, click here.
Below are the most recent publications written about "HIV Envelope Protein gp41" by people in Profiles.
-
Design and Biological Evaluation of m-Xylene Thioether-Stapled Short Helical Peptides Targeting the HIV-1 gp41 Hexameric Coiled-Coil Fusion Complex. J Med Chem. 2019 10 10; 62(19):8773-8783.
-
Long-Acting HIV-1 Fusion Inhibitory Peptides and their Mechanisms of Action. Viruses. 2019 09 02; 11(9).
-
Development of Protein- and Peptide-Based HIV Entry Inhibitors Targeting gp120 or gp41. Viruses. 2019 08 01; 11(8).
-
New mechanisms of resistance in virological failure to protease inhibitors: selection of non-described protease, Gag and Gp41 mutations. J Antimicrob Chemother. 2019 07 01; 74(7):2019-2023.
-
HIV-1 protease, Gag and gp41 baseline substitutions associated with virological response to a PI-based regimen. J Antimicrob Chemother. 2019 06 01; 74(6):1679-1692.
-
Effects of the SOS (A501C/T605C) and DS (I201C/A433C) Disulfide Bonds on HIV-1 Membrane Envelope Glycoprotein Conformation and Function. J Virol. 2019 06 15; 93(12).
-
Massively Parallel Profiling of HIV-1 Resistance to the Fusion Inhibitor Enfuvirtide. Viruses. 2019 05 15; 11(5).
-
Anti-gp41 antibody levels reflect HIV viral suppression and cellular reservoir in long-term antiretroviral-treated trial participants. J Antimicrob Chemother. 2019 05 01; 74(5):1389-1394.
-
Reverse Immunology Approach to Define a New HIV-gp41-Neutralizing Epitope. J Immunol Res. 2019; 2019:9804584.
-
A Peptide-Based HIV-1 Fusion Inhibitor with Two Tail-Anchors and Palmitic Acid Exhibits Substantially Improved In Vitro and Ex Vivo Anti-HIV-1 Activity and Prolonged In Vivo Half-Life. Molecules. 2019 Mar 21; 24(6).